Necroptosis signaling in liver diseases: An update.
MLKL
Necroptosis
RIPK3
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
11
06
2019
revised:
11
08
2019
accepted:
29
08
2019
pubmed:
3
9
2019
medline:
1
7
2020
entrez:
3
9
2019
Statut:
ppublish
Résumé
The apoptosis alternate cell death pathways are extensively studied in recent years and their significance has been well recognized. With identification of newer cell death pathways, the therapeutic opportunities to modulate cell death have indeed further extended. Necroptosis, among other apoptosis alternate pathways, has been immensely studied recently in different hepatic disease models. Receptor-interacting protein 1 (RIPK1), RIPK3 and mixed lineage kinase domain like (MLKL) seemed to be the key players to mediate necroptosis pathway. Initially, necroptosis seemed to be following the typical pathway. But recently diverse pathways and outcomes have been observed. With recent studies reporting diverse outcomes, the necroptosis signalling has become a lot more interesting and intricate. The typical RIPK1 signalling followed by RIPK3 and MLKL might not always be strictly followed. Although, necroptosis signalling has been intensively investigated in various disease conditions; however, there is still a need to further elaborate and understand the unique scaffolding and kinase properties and other signalling interactions of necroptosis signalling molecules.
Identifiants
pubmed: 31476369
pii: S1043-6618(19)31073-4
doi: 10.1016/j.phrs.2019.104439
pii:
doi:
Substances chimiques
Protein Kinases
EC 2.7.-
Receptor-Interacting Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104439Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.